DK1820494T3 - Mikropartikler bestående af estradiol og cholesterol - Google Patents

Mikropartikler bestående af estradiol og cholesterol

Info

Publication number
DK1820494T3
DK1820494T3 DK07008942T DK07008942T DK1820494T3 DK 1820494 T3 DK1820494 T3 DK 1820494T3 DK 07008942 T DK07008942 T DK 07008942T DK 07008942 T DK07008942 T DK 07008942T DK 1820494 T3 DK1820494 T3 DK 1820494T3
Authority
DK
Denmark
Prior art keywords
estradiol
cholesterol
microparticles consisting
progesterone
particles
Prior art date
Application number
DK07008942T
Other languages
English (en)
Inventor
John Claude Savoir
Uribe Juan Angeles
Original Assignee
Skendi Finance Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1820494(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skendi Finance Ltd filed Critical Skendi Finance Ltd
Application granted granted Critical
Publication of DK1820494T3 publication Critical patent/DK1820494T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07008942T 2003-06-13 2004-06-10 Mikropartikler bestående af estradiol og cholesterol DK1820494T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47793903P 2003-06-13 2003-06-13
EP20040736545 EP1663161B1 (en) 2003-06-13 2004-06-10 Slow release estradiol-progesterone formulation

Publications (1)

Publication Number Publication Date
DK1820494T3 true DK1820494T3 (da) 2010-05-25

Family

ID=33551788

Family Applications (3)

Application Number Title Priority Date Filing Date
DK04736545.7T DK1663161T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse
DK07008938.8T DK1844765T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse
DK07008942T DK1820494T3 (da) 2003-06-13 2004-06-10 Mikropartikler bestående af estradiol og cholesterol

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK04736545.7T DK1663161T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse
DK07008938.8T DK1844765T3 (da) 2003-06-13 2004-06-10 Estradiol-progesteron-formulering med langsom afgivelse

Country Status (24)

Country Link
US (2) US7589082B2 (da)
EP (3) EP1844765B1 (da)
JP (2) JP4956185B2 (da)
CN (2) CN100594907C (da)
AT (1) ATE454885T1 (da)
AU (1) AU2004246870B2 (da)
BR (1) BRPI0411335A (da)
CA (2) CA2528545C (da)
CY (1) CY1109967T1 (da)
DE (1) DE602004025156D1 (da)
DK (3) DK1663161T3 (da)
EA (3) EA026709B1 (da)
ES (3) ES2537551T3 (da)
HK (4) HK1097735A1 (da)
HU (1) HUE025147T2 (da)
IL (2) IL172466A (da)
MX (1) MX2008014654A (da)
NO (1) NO341540B1 (da)
OA (1) OA13307A (da)
PL (3) PL1820494T3 (da)
PT (3) PT1663161E (da)
SI (3) SI1844765T1 (da)
TW (1) TWI336623B (da)
WO (1) WO2004110408A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1820494T3 (pl) 2003-06-13 2010-07-30 Skendi Finance Ltd Mikrocząstki składające się z estradiolu i cholesterolu
CN102056611A (zh) * 2008-04-14 2011-05-11 Posi维森纳里解决方案有限责任公司 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180123165A (ko) * 2016-04-01 2018-11-14 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
EP3272732B1 (de) 2016-07-19 2019-09-18 Evonik Degussa GmbH Verfahren zur alkoxycarbonylierung ethylenisch ungesättigter verbindungen mit monophosphinliganden
CN113423391A (zh) * 2018-11-29 2021-09-21 因斯格纳公司 作为不育剂的苯甲酸雌二醇
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3954364A1 (en) * 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1367608A (en) 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
US5023092A (en) * 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
SE9301171D0 (sv) 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
FR2747042B1 (fr) * 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
EP0888790A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Drug particle delivery device
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
ES2253451T3 (es) * 2000-12-14 2006-06-01 Ortho-Mcneil Pharmaceutical, Inc. Productos a base de hormona esteroide y sus procedimientos de fabricacion.
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
PL1820494T3 (pl) 2003-06-13 2010-07-30 Skendi Finance Ltd Mikrocząstki składające się z estradiolu i cholesterolu

Also Published As

Publication number Publication date
AU2004246870A1 (en) 2004-12-23
CN100594907C (zh) 2010-03-24
CN101816662A (zh) 2010-09-01
IL172466A0 (en) 2006-04-10
EP1844765B1 (en) 2015-01-21
PL1844765T3 (pl) 2015-06-30
CY1109967T1 (el) 2014-09-10
HUE025147T2 (hu) 2016-03-29
IL172466A (en) 2011-11-30
EA012783B1 (ru) 2009-12-30
EP1820494A3 (en) 2007-09-19
CA2849228C (en) 2016-09-20
PT1663161E (pt) 2015-05-13
IL210851A0 (en) 2011-04-28
EA201201221A1 (ru) 2014-02-28
EP1663161B1 (en) 2015-01-14
SI1820494T1 (sl) 2010-08-31
NO20060200L (no) 2006-01-13
PT1820494E (pt) 2010-04-14
WO2004110408A3 (en) 2005-04-14
TWI336623B (en) 2011-02-01
CA2849228A1 (en) 2004-12-23
EP1820494B1 (en) 2010-01-13
NO341540B1 (no) 2017-12-04
JP4956185B2 (ja) 2012-06-20
CA2528545A1 (en) 2004-12-23
MX2008014654A (es) 2009-03-09
SI1844765T1 (sl) 2015-05-29
PL1663161T3 (pl) 2015-08-31
JP2006527263A (ja) 2006-11-30
EA200900451A1 (ru) 2009-12-30
HK1097735A1 (en) 2007-07-06
ES2537551T3 (es) 2015-06-09
EP1820494A2 (en) 2007-08-22
US20050025827A1 (en) 2005-02-03
US8163722B2 (en) 2012-04-24
DK1663161T3 (da) 2015-04-27
US20090081303A1 (en) 2009-03-26
ES2537563T3 (es) 2015-06-09
HK1147426A1 (en) 2011-08-12
BRPI0411335A (pt) 2006-07-25
PL1820494T3 (pl) 2010-07-30
HK1109586A1 (en) 2008-06-13
TW200514560A (en) 2005-05-01
IL210851A (en) 2016-05-31
EA200600029A1 (ru) 2006-08-25
ATE454885T1 (de) 2010-01-15
EA018356B1 (ru) 2013-07-30
US7589082B2 (en) 2009-09-15
JP2011157386A (ja) 2011-08-18
AU2004246870B2 (en) 2009-07-23
ES2340422T3 (es) 2010-06-02
WO2004110408A2 (en) 2004-12-23
EP1844765A1 (en) 2007-10-17
SI1663161T1 (sl) 2015-05-29
CN1835737A (zh) 2006-09-20
CN101816662B (zh) 2015-01-28
EP1663161A2 (en) 2006-06-07
HK1106717A1 (en) 2008-03-20
EA026709B1 (ru) 2017-05-31
DE602004025156D1 (de) 2010-03-04
OA13307A (en) 2007-04-13
DK1844765T3 (da) 2015-04-27
PT1844765E (pt) 2015-05-20
CA2528545C (en) 2014-08-12

Similar Documents

Publication Publication Date Title
DK1820494T3 (da) Mikropartikler bestående af estradiol og cholesterol
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
HUP0402661A3 (en) Formulation and dosage form for the controlled delivery of therapeutic agents
IL153497A0 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
TW200621291A (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
HUP0300335A2 (hu) 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
AR033042A1 (es) Terapia de reemplazo hormonal
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
WO2005007117A3 (en) Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
EP1545622A4 (en) MUCOADHûSIVE COMPOSITION AND FORMULATION FOR SOLUBILIZING UNCLEANED MEDICAMENTS AND MANUFACTURING METHOD DAF R
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
NO20026055L (no) Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene
WO2004011029A3 (en) Pharmaceutical compositions for penis enlargement
HUP0302984A2 (hu) Buprenorphin felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
CY1116203T1 (el) Σκευασμα οιστραδιολης-προγεστερονης βραδειας αποδεσμευσης
WO2001023563A3 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
IL163431A (en) 1 - phenyl - 2 - heteroaryl - substituted benzimidazole derivatives and the use thereof for producing drugs used in the treatment of immunological diseases
GB0007788D0 (en) Method to evaluate the therapeutic and toxic effects related to drug administration